Fisher Asset Management
BMRN icon

Fisher Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fisher Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Sell
35,389
-91
-0.3% -$4.99K ﹤0.01% 587
2026
Q1 		$2M Buy
35,480
+190
+0.5% +$11.1K ﹤0.01% 574
2025
Q4 		$2.1M Buy
35,290
+3,564
+11% +$194K ﹤0.01% 552
2025
Q3 		$1.72M Buy
31,726
+18,181
+134% +$1.04M ﹤0.01% 601
2025
Q2 		$745K Sell
13,545
-28
-0.2% -$1.65K ﹤0.01% 732
2025
Q1 		$960K Sell
13,573
-393
-3% -$26.4K ﹤0.01% 686
2024
Q4 		$918K Buy
13,966
+420
+3% +$28.1K ﹤0.01% 670
2024
Q3 		$952K Buy
13,546
+122
+0.9% +$10.2K ﹤0.01% 665
2024
Q2 		$1.11M Sell
13,424
-75
-0.6% -$6.24K ﹤0.01% 668
2024
Q1 		$1.18M Buy
13,499
+9
+0.1% +$806 ﹤0.01% 665
2023
Q4 		$1.3M Buy
+13,490
New +$1.19M ﹤0.01% 655

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fisher Asset Management's BMRN Position: Q2 2026 in Review

Fisher Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.26% in Q2 2026, selling an estimated $4.99K and leaving 35,389 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Fisher Asset Management first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.1M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Fisher Asset Management held 35,389 shares of BioMarin Pharmaceuticals worth $2.02M as of Q2 2026.
  • Fisher Asset Management sold 91 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.99K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #587 holding.
  • Fisher Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Fisher Asset Management's BioMarin Pharmaceuticals position peaked at $2.1M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.